UBS Group »

Sarepta Therapeutics Inc Note 1.250 9/1 shares owned by UBS Group

Quarter-by-quarter ownership of Sarepta Therapeutics Inc Note 1.250 9/1 shares owned by UBS Group from 13F filings

Historical chart of UBS Group investment in Sarepta Therapeutics Inc Note 1.250 9/1

Tip: Access up to 7 years of quarterly data

All positions including Sarepta Therapeutics Inc Note 1.250 9/1 held by UBS Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sarepta Therapeutics Inc Note 1.250 9/1 by UBS Group

Quarter filed Position value Share count Share price at filing
2025-09-30 $440 500 0.88
2025-06-30 $360 500 0.72
2025-03-31 $464 500 0.93
2024-12-31 $549 500 1.10
2024-09-30 $567 500 1.13

More positions owned by UBS Group

Spdr S&p 500 Etf Tr Tr Unit (SPY)
NVIDIA Corporation (NVDA)
Microsoft Corporation (MSFT)
Apple (AAPL)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Amazon (AMZN)
Broadcom (AVGO)
Meta Platforms Cl A (META)
Alphabet Cap Stk Cl A (GOOGL)
JPMorgan Chase & Co. (JPM)
Alphabet Cap Stk Cl C (GOOG)
Ubs Group SHS (UBS)
Tesla Motors (TSLA)
Ishares Tr Russell 2000 Etf (IWM)
Visa Com Cl A (V)

View all positions for UBS Group

Top funds holding Sarepta Therapeutics Inc Note 1.250 9/1

Balyasny Asset Management
Linden Advisors
Highbridge Capital Management
Oaktree Capital Management
D. E. Shaw & Co
DG Capital Management
Calamos Advisors
Davidson Kempner Capital Management
Agf Management
Readystate Asset Management
LMR Partners
State Street Corporation
Silver Point Capital
Man Group
Capstone Investment Advisors

View all funds holding Sarepta Therapeutics Inc Note 1.250 9/1